Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Today sector : Health technology save search
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Published: 2024-04-23 (Crawled : 05:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 4.32%
H: 0.0%
C: 0.0%
MOR | News | $18.04 0.45% 0.44% 180K
|
Health Technology
|
| O: 0.39%
H: 0.0%
C: 0.0%
sales expansion novartis growth
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Published: 2024-04-23 (Crawled : 05:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
study
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm
Published: 2024-04-23 (Crawled : 05:00) - prnewswire.com
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: -3.99%
H: 0.0%
C: 0.0%
Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion, Globally, by 2032 at 7.4% CAGR: Allied Market Research
Published: 2024-04-23 (Crawled : 05:00) - prnewswire.com
NVRO | $12.79 4.24% 0.0% 410K
|
Health Technology
|
| O: 5.28%
H: 0.0%
C: 0.0%
BSX | $68.99 1.43% 0.19% 9.1M
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: 0.0%
LIVN | $55.01 1.85% 1.82% 640K
|
Health Technology
|
| O: 2.7%
H: 0.0%
C: 0.0%
ECOR | $5.9 4.98% 4.75% 7.3K
|
Health Technology
|
| O: 4.98%
H: 0.0%
C: 0.0%
reach research market
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Published: 2024-04-23 (Crawled : 05:00) - prnewswire.com
VRTX | $404.93 1.25% 1.43% 1.1M
|
Health Technology
|
| O: 1.87%
H: 0.0%
C: 0.0%
cell for collaboration therapeutics diabetes agreement
HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
| Email alert
Add to watchlist
publication treatment research preclinical for leukemia
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Evolv Technologies Holdings, Inc. with Losses of $100,000 to Contact the Firm
Published: 2024-04-23 (Crawled : 08:00) - prnewswire.com
EVLV | News | $4.18 7.73% 7.18% 1.3M
|
|
| O: 1.3%
H: 0.0%
C: 0.0%
IESC | News | $127.8 8.6% 7.92% 170K
|
Industrial Services
|
| O: 3.16%
H: 0.0%
C: 0.0%
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: -3.99%
H: 0.0%
C: 0.0%
Zealand Pharma Partners with Benchling to Advance R&D of Engineered Peptide Medicines
Published: 2024-04-23 (Crawled : 08:00) - prnewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma
Danaher Reports First Quarter 2024 Results
Published: 2024-04-23 (Crawled : 10:00) - prnewswire.com
DHR | $253.11 7.21% 0.0% 6.8M
|
Health Technology
|
| O: 8.12%
H: 0.0%
C: 0.0%
first results
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: 13.3%
H: 0.0%
C: 0.0%
atile-002 versamune biotech hpv cancer key trial
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 1.5%
H: 0.0%
C: 0.0%
pharmaceuticals financial results
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
PHGE | $0.3465 17.42% 1.01% 220K
|
Health Technology
|
| O: 6.03%
H: 0.0%
C: 0.0%
bx004 congress treatment fibrosis for infections study
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.0%
H: 0.0%
C: 0.0%
KNSA | $17.66 3.31% 3.2% 610K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
first pharmaceuticals financial results
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
DARE | $0.306 3.62% 3.5% 320K
|
Health Technology
|
| O: 6.99%
H: 0.0%
C: 0.0%
bioscience contraceptive grant technology funding development
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
AGEN A | $6.44 11.61% 10.4% 1.7M
|
Health Technology
|
| O: 7.29%
H: 0.0%
C: 0.0%
first report update financial
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 4.09%
H: 0.0%
C: 0.0%
lung approval cancer cell treatment for
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
UBX | $1.48 0.0% 34K
|
Health Technology
| Email alert
Add to watchlist
ubx1325 aspire extension study
Todays' Top-5
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
INMB | News 0 d | $10.12 -4.75% -4.99% 180K
|
Health Technology
|
| O: 17.47%
H: 0.0%
C: 0.0%
assay for commercial development
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
EDAP | $7.13 -0.28% -0.28% 18K
|
Health Technology
| Email alert
Add to watchlist
one association meeting results study
Ionis to hold first quarter 2024 financial results webcast
Published: 2024-04-23 (Crawled : 11:00) - prnewswire.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
first financial results
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.